Subscribe to RSS
Featured Cannabis News
Cato Scholar Statement: Don’t Let Cannabis Data Spark a Moral Panic
The reported rise in problematic cannabis use deserves attention, but it shouldn’t become the basis for a new moral panic. After alcohol prohibition ended, drinking increased for decades before declining as Americans developed knowledge and social norms around responsible use. Cannabis may be undergoing a similar adjustment. Indeed, a five-year Canadian study found that cannabis misuse declined after legalization, with frequent pre-legalization users reducing both their use and misuse. We should educate people about cannabis’s risks, not assume that today’s trends represent the long-run effects of legalization—or that prohibition is the answer.
Cato Institute Aug.21, 2026Aurora Accuses Curaleaf of ‘Pressuring Shareholders’ as it Launches Official Takeover Bid
Curaleaf Holdings has pushed ahead with its unexpected and unsolicited acquisition campaign of Aurora Cannabis and has now submitted an official bid for its Canadian rival.
The cannabis giant formally launched its takeover bid on August 18, 2026, meaning Aurora’s shareholders must make a decision before the end of the year.
‘Marijuana Can No Longer Remain in Schedule I’: Inside the Government’s Final Case for Rescheduling Weed—and the Witnesses It Tore Apart
The federal government’s closing argument for moving marijuana to Schedule III is in, and its lawyers did not hedge. “Marijuana can no longer remain in Schedule I,” the DEA’s attorneys wrote in a post-hearing brief filed August 17 with Chief Administrative Law Judge Derek C. Julius, asking the judge to “expeditiously recommend” the transfer..
Curaleaf Officially Launches Hostile Takeover Bid for Aurora Cannabis
Curaleaf said it has formally commenced its previously announced proposal to purchase Aurora Cannabis.
Under the terms of the offer, Aurora shareholders would receive a consideration of $4 per Aurora common share, comprised of 0.3463 of a Curaleaf subordinate voting share plus $0.75 in cash. Curaleaf said that, based on Aurora's 30-day volume weighted average price, the offer implies a 45% premium to the unaffected share price.